PSMA6 and benign prostatic hyperplasia: In 2022, Blair reviewed HSE (Permixon®) for the symptomatic relief of BPH symptoms by examining 21 different studies (representing 361 patients) that, in some cases, specifically compared Permixon® to alpha-1 blockers or 5α-reductase inhibitors [152].